6533b827fe1ef96bd1286dee
RESEARCH PRODUCT
Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97
Marc ThillVolkmar MüllerV. TierbachThomas DeckerJenny FurlanettoChristoph MundhenkeMartina SchmidtS. LoiblCarsten DenkertF. SeitherK Lübbesubject
Oncologymedicine.medical_specialtybusiness.industryHER2 negativeRibociclibHematologymedicine.diseaseMetastatic breast cancerOncologyHormone receptorInternal medicinemedicineFirst line chemotherapybusinessHormoneyear | journal | country | edition | language |
---|---|---|---|---|
2018-10-01 | Annals of Oncology |